MedTrace Logo

ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

NCT06775860 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 552

Last updated 2025-09-08

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of oral ICP-332 in subjects with moderate to severe atopic dermatitis

Conditions

Interventions

DRUG

ICP-332 Tablets

ICP-332 will be administered as tablet

DRUG

ICP-332 Placebo Tablets

ICP-332 Placebo will be administered as tablet

Sponsors & Collaborators

  • Beijing InnoCare Pharma Tech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2026-11-25
Completion
2026-12-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06775860 on ClinicalTrials.gov